
Bonaventura Clotet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11902168/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 171.	7.4	1,076
2	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine, 2008, 359, 1429-1441.	27.0	708
3	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354.	27.0	699
4	Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia. New England Journal of Medicine, 2003, 348, 2186-2195.	27.0	676
5	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. JAMA - Journal of the American Medical Association, 2000, 283, 2417.	7.4	647
6	Antiretroviral Drug Resistance Testing in Adults With HIV Infection. JAMA - Journal of the American Medical Association, 1998, 279, 1984.	7.4	528
7	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet, The, 2007, 369, 1169-1178.	13.7	506
8	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine, 2010, 16, 460-465.	30.7	500
9	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365.	27.0	498
10	Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel. Clinical Infectious Diseases, 2003, 37, 113-128.	5.8	495
11	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2007, 370, 39-48.	13.7	437
12	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet, The, 2014, 383, 2222-2231.	13.7	430
13	Antiretroviral Drug Resistance Testing in Adult HIVâ€1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. Clinical Infectious Diseases, 2008, 47, 266-285.	5.8	428
14	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet, The, 2011, 378, 229-237.	13.7	352
15	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	9.1	345
16	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	6.1	328
17	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. The, 2006, 368, 466-475.	13.7	326
18	Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infectious Diseases, The, 2021, 21, 629-636.	9.1	303

#	Article	IF	CITATIONS
19	The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids, 2007, 21, 1273-1281.	2.2	287
20	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. Journal of Infectious Diseases, 2013, 207, 740-748.	4.0	271
21	Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. Aids, 2002, 16, 209-218.	2.2	267
22	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2021, 73, e4073-e4081.	5.8	219
23	Transmission of Drugâ€Resistant HIVâ€1 Is Stabilizing in Europe. Journal of Infectious Diseases, 2009, 200, 1503-1508.	4.0	213
24	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. Aids, 2001, 15, 2407-2414.	2.2	212
25	Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood, 2009, 113, 2732-2741.	1.4	208
26	Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. PLoS Biology, 2012, 10, e1001448.	5.6	208
27	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 221-228.	2.1	203
28	Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids, 2002, 16, 2385-2390.	2.2	197
29	Longâ€Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatmentâ€Experienced Patients with Drugâ€Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. Clinical Infectious Diseases, 2010, 50, 605-612.	5.8	196
30	A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational Medicine, 2013, 5, 166ra2.	12.4	193
31	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. Aids, 2000, 14, 397-403.	2.2	189
32	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV,the, 2015, 2, e127-e136.	4.7	180
33	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine, 2021, 384, 417-427.	27.0	179
34	Secretion of interferonâ€Î³ by human macrophages demonstrated at the singleâ€cell level after costimulation with interleukin (IL)â€12 plus ILâ€18. Immunology, 2009, 126, 386-393.	4.4	173
35	Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression. Clinical Infectious Diseases, 2002, 34, 504-510.	5.8	170
36	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infectious Diseases, The, 2012, 12, 27-35.	9.1	160

#	Article	IF	CITATIONS
37	Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 39-46.	2.1	155
38	Detection of SARS-CoV-2 in a cat owned by a COVID-19â^'affected patient in Spain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24790-24793.	7.1	154
39	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids, 2003, 17, 987-999.	2.2	151
40	Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 404-412.	2.1	151
41	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 33-42.	2.1	151
42	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 229-236.	2.1	143
43	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. Aids, 2010, 24, 2827-2833.	2.2	140
44	HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. Aids, 2001, 15, F19-F27.	2.2	135
45	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIVâ€Infected Patients: Clinical Implications. Clinical Infectious Diseases, 2010, 50, 1300-1308.	5.8	133
46	Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals. Journal of Virology, 2001, 75, 10319-10325.	3.4	127
47	A Doubleâ€Blind, Placeboâ€Controlled Trial of Maraviroc in Treatmentâ€Experienced Patients Infected with Nonâ€R5 HIVâ€1. Journal of Infectious Diseases, 2009, 199, 1638-1647.	4.0	127
48	Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 252-261.	2.5	125
49	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infectious Diseases, The, 2013, 13, 587-596.	9.1	119
50	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Molecular Pharmacology, 1998, 53, 340-345.	2.3	118
51	Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. Aids, 1998, 12, 1015-1020.	2.2	118
52	Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells. Journal of Immunology, 2014, 193, 1988-1997.	0.8	118
53	CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. PLoS ONE, 2012, 7, e29717.	2.5	117
54	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. Aids, 2010, 24, 959-968.	2.2	114

#	Article	IF	CITATIONS
55	Efficacy of Lowâ€Dose Subcutaneous Interleukinâ€2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus Load. Journal of Infectious Diseases, 1999, 180, 56-60.	4.0	110
56	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. Aids, 2005, 19, 2117-2125.	2.2	109
57	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. Antiviral Therapy, 2012, 17, 355-364.	1.0	108
58	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. Molecular Pharmacology, 1999, 55, 67-73.	2.3	107
59	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
60	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Aids, 2004, 18, 459-463.	2.2	103
61	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117.	3.2	101
62	Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 1907-1914.	3.2	101
63	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
64	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 403-408.	5.8	100
65	Virological rebound after suppression on highly active antiretroviral therapy. Aids, 2003, 17, 1741-1751.	2.2	99
66	Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission. Journal of Virology, 2007, 81, 7559-7570.	3.4	99
67	Natural History of Human Papillomavirus Infections Involving Anal, Penile, and Oral Sites Among HIV-Positive Men. Sexually Transmitted Diseases, 2013, 40, 3-10.	1.7	98
68	Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy, 2010, 15, 1045-1052.	1.0	96
69	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. Aids, 2002, 16, 1009-1017.	2.2	92
70	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. Aids, 2002, 16, 1383-1389.	2.2	92
71	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. Journal of Translational Medicine, 2013, 11, 68.	4.4	92
72	Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. Journal of Virology, 1999, 73, 5577-5585.	3.4	90

#	Article	IF	CITATIONS
73	High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells. Journal of Biological Chemistry, 2004, 279, 51305-51314.	3.4	89
74	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2008, 24, 1301-1307.	1.1	87
75	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	2.1	86
76	Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. Aids, 2002, 16, 895-899.	2.2	85
77	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids, 2007, 21, 721-732.	2.2	85
78	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. Journal of Translational Medicine, 2015, 13, 60.	4.4	84
79	Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 413-421.	2.1	83
80	Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. Journal of Experimental Medicine, 2006, 203, 529-539.	8.5	81
81	Sequence Homology Required by Human Immunodeficiency Virus Type 1 To Escape from Short Interfering RNAs. Journal of Virology, 2006, 80, 571-577.	3.4	81
82	Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. Aids, 1999, 13, F1-F8.	2.2	81
83	Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. Aids, 1999, 13, 1045-1049.	2.2	80
84	Immunodiscordant responses to HAART – mechanisms and consequences. Expert Review of Clinical Immunology, 2013, 9, 1135-1149.	3.0	79
85	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. Aids, 1998, 12, 2007-2015.	2.2	77
86	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). Aids, 2008, 22, 1313-1322.	2.2	77
87	Clinical management of HIV-1 resistance. Antiviral Research, 2010, 85, 245-265.	4.1	77
88	RNA interference of HIV replication. Trends in Immunology, 2002, 23, 559-561.	6.8	75
89	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. Aids, 2005, 19, 569-575.	2.2	75
90	The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. Aids, 1999, 13, 909-917.	2.2	74

#	Article	IF	CITATIONS
91	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. Aids, 2007, 21, 169-178.	2.2	74
92	A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 290-297.	2.1	73
93	Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. Journal of Infection, 2021, 82, 186-230.	3.3	73
94	Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 1365-1372.	9.1	73
95	IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients. PLoS ONE, 2010, 5, e13771.	2.5	71
96	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. Virology, 2003, 305, 318-329.	2.4	70
97	Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. Aids, 2009, 23, 183-188.	2.2	70
98	Evolution of the gut microbiome following acute HIV-1 infection. Microbiome, 2019, 7, 73.	11.1	69
99	Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2009, 53, 1937-1943.	3.2	68
100	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 558-567.	2.5	66
101	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. Aids, 2004, 18, 1137-1146.	2.2	64
102	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 229-236.	2.1	63
103	HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Research, 2003, 59, 137-142.	4.1	63
104	High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. Aids, 2006, 20, 1201-1204.	2.2	63
105	A clathrin–dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell–T cell transmission. Antiviral Research, 2008, 80, 185-193.	4.1	62
106	Drug uptake transporters in antiretroviral therapy. , 2011, 132, 268-279.		62
107	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. Aids, 2014, 28, 325-334.	2.2	62
108	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Aids, 2001, 15, 2385-2395.	2.2	61

#	Article	IF	CITATIONS
109	Effectiveness of Mindfulness-Based Cognitive Therapy on the Quality of Life, Emotional Status, and CD4 Cell Count of Patients Aging with HIV Infection. AIDS and Behavior, 2014, 18, 676-685.	2.7	61
110	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nature Communications, 2018, 9, 2739.	12.8	61
111	Human Immunodeficiency Virus Type 1 Genetic Evolution in Patients with Prolonged Suppression of Plasma Viremia. Virology, 1999, 256, 180-187.	2.4	60
112	The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 51-56.	3.2	59
113	Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. Aids, 2010, 24, 857-865.	2.2	59
114	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. Aids, 2016, 30, 221-230.	2.2	59
115	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. Antiviral Therapy, 2004, 9, 465-478.	1.0	58
116	Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies. Journal of Virology, 2007, 81, 2485-2496.	3.4	56
117	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	3.0	56
118	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
119	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunology, 2019, 12, 232-246.	6.0	56
120	Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026. Molecular Pharmacology, 2008, 73, 1264-1273.	2.3	55
121	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathogens, 2011, 7, e1002314.	4.7	55
122	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Frontiers in Immunology, 2020, 11, 823.	4.8	55
123	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. Aids, 2000, 14, 727-732.	2.2	53
124	Evaluation of the anti-HIV activity of statins. Aids, 2005, 19, 1697-1700.	2.2	53
125	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clinical Infectious Diseases, 2008, 47, 1468-1475.	5.8	53
126	Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2002, 76, 968-979.	3.4	52

#	Article	IF	CITATIONS
127	Restriction of HIV-1 Replication in Primary Macrophages by IL-12 and IL-18 through the Upregulation of SAMHD1. Journal of Immunology, 2013, 190, 4736-4741.	0.8	52
128	CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV,the, 2015, 2, e236-e242.	4.7	52
129	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). EClinicalMedicine, 2019, 11, 65-80.	7.1	52
130	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. Journal of Leukocyte Biology, 2004, 76, 804-811.	3.3	51
131	Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIVâ€1–Infected Patients with Virological Failure. Clinical Infectious Diseases, 2010, 50, 872-881.	5.8	51
132	p21 regulates the HIV-1 restriction factor SAMHD1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1322-4.	7.1	51
133	Monitoring Natural SARS-CoV-2 Infection in Lions (Panthera leo) at the Barcelona Zoo: Viral Dynamics and Host Responses. Viruses, 2021, 13, 1683.	3.3	51
134	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	1.0	51
135	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Therapy, 2009, 14, 195-201.	1.0	51
136	Impact of Nevirapine on Lipid Metabolism. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, S79-S84.	2.1	50
137	The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. Aids, 2000, 14, 781-789.	2.2	49
138	Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses, 2006, 22, 321-329.	1.1	48
139	TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals. AIDS Patient Care and STDs, 2007, 21, 533-543.	2.5	48
140	Diarylpyrimidineâ^'Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. Journal of Medicinal Chemistry, 2011, 54, 3091-3096.	6.4	47
141	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. Aids, 2004, 18, 819-821.	2.2	46
142	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology, 2008, 5, 32.	2.0	46
143	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 324-333.	2.1	46
144	HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. Aids, 2008, 22, 23-31.	2.2	46

#	Article	IF	CITATIONS
145	Prevalence, Clearance, and Incidence of Human Papillomavirus Type–Specific Infection at the Anal and Penile Site of HIV-Infected Men. Sexually Transmitted Diseases, 2013, 40, 611-618.	1.7	46
146	The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology, 2005, 343, 141-149.	2.4	45
147	Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 47-52.	2.1	45
148	Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity. Aids, 2014, 28, 2213-2222.	2.2	45
149	Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. Aids, 2005, 19, 343-5.	2.2	45
150	Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach. Antiviral Therapy, 2004, 9, 335-342.	1.0	45
151	Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 1293-1297.	1.1	44
152	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. Aids, 2012, 26, 2285-2293.	2.2	44
153	Distribution of Human Papillomavirus Genotypes in Anal Cytological and Histological Specimens from HIV-Infected Men Who Have Sex with Men and Men Who Have Sex with Women. Diseases of the Colon and Rectum, 2013, 56, 1043-1052.	1.3	44
154	M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. Aids, 2002, 16, 1686-1689.	2.2	44
155	Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection. Aids, 2004, 18, 59-66.	2.2	43
156	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids, 2008, 22, 367-376.	2.2	43
157	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. Aids, 2011, 25, 1683-1690.	2.2	43
158	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy, 2014, 69, 3368-3371.	3.0	43
159	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infectious Diseases, 2014, 14, 407.	2.9	43
160	RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Scientific Reports, 2017, 7, 13339.	3.3	43
161	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, , 221-228.	2.1	42
162	ZNRD1 (Zinc Ribbon Domain–Containing 1) Is a Host Cellular Factor That Influences HIVâ€1 Replication and Disease Progression. Clinical Infectious Diseases, 2010, 50, 1022-1032.	5.8	42

#	Article	IF	CITATIONS
163	Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. Journal of Infection, 2021, 82, 269-275.	3.3	42
164	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. Aids, 2006, 20, 2075-2080.	2.2	41
165	Assessing Self-Reported Adherence to HIV Therapy by Questionnaire: The SERAD (Self-Reported) Tj ETQq1 1 0.784	4314 rgBT 1.1	/Overlock 1
166	Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3. HIV Clinical Trials, 2007, 8, 213-220.	2.0	41
167	Onceâ€daily dolutegravir is superior to onceâ€daily darunavir/ritonavir in treatmentâ€naÃ⁻ve HIVâ€1â€positive individuals: 96 week results from FLAMINGO. Journal of the International AIDS Society, 2014, 17, 19490.	3.0	41
168	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. Journal of Virology, 2002, 76, 10546-10552.	3.4	40
169	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. Aids, 2011, 25, 27-36.	2.2	40
170	Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages. Cell Cycle, 2015, 14, 1657-1665.	2.6	40
171	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Research, 2012, 96, 65-69.	4.1	39
172	Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. Journal of Antimicrobial Chemotherapy, 2016, 71, 387-394.	3.0	39
173	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Frontiers in Microbiology, 2022, 13, .	3.5	39
174	Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: Evidence of GBV-C/HGV sexual transmission. , 1998, 55, 293-299.		38
175	On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology, 2009, 6, 89.	2.0	38
176	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
177	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology, 2013, 10, 42.	2.0	38
178	Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study. Clinical Infectious Diseases, 2020, 71, 390-399.	5.8	38
179	Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. Aids, 1998, 12, 697-704.	2.2	37
180	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. Journal of General Virology, 2003, 84, 2217-2228.	2.9	37

#	Article	IF	CITATIONS
181	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Aids, 2008, 22, 2187-2198.	2.2	37
182	Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer. Journal of Virology, 2012, 86, 8773-8780.	3.4	37
183	Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. Aids, 2001, 15, 1894-1896.	2.2	37
184	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. AIDS Research and Human Retroviruses, 2000, 16, 627-634.	1.1	36
185	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 1008-1012.	4.0	36
186	Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology, 2004, 326, 103-112.	2.4	35
187	Benefits and concerns of simplification strategies in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2006, 58, 235-242.	3.0	35
188	Herb-Drug Interaction betweenEchinacea purpureaand Darunavir-Ritonavir in HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 326-330.	3.2	35
189	Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain, Behavior, and Immunity, 2012, 26, 568-572.	4.1	35
190	Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients. PLoS ONE, 2012, 7, e31016.	2.5	35
191	Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. Journal of Virological Methods, 1998, 73, 77-82.	2.1	34
192	Enfuvirtide (Tâ€20) Crossâ€Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide. Journal of Infectious Diseases, 2003, 188, 1827-1833.	4.0	34
193	IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. Aids, 2014, 28, 133-136.	2.2	34
194	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. Clinical Infectious Diseases, 2019, 68, 597-606.	5.8	34
195	Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology, 2007, 45, 899-910.	7.3	33
196	Cell adhesion through αV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood, 2009, 113, 1278-1286.	1.4	33
197	The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. Aids, 2010, 24, 17-25.	2.2	33
198	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. Journal of Translational Medicine, 2015, 13, 230.	4.4	33

#	Article	IF	CITATIONS
199	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. Journal of Virology, 2015, 89, 9189-9199.	3.4	33
200	Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. Clinical Pharmacokinetics, 2013, 52, 543-553.	3.5	32
201	The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells. PLoS Pathogens, 2016, 12, e1005829.	4.7	32
202	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. PLoS ONE, 2014, 9, e94495.	2.5	32
203	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Research, 2002, 53, 1-8.	4.1	31
204	Immunological and virological study of enfuvirtide-treated HIV-positive patients. Aids, 2004, 18, 1673-1682.	2.2	31
205	Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens. Antimicrobial Agents and Chemotherapy, 2011, 55, 2872-2879.	3.2	31
206	Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. Journal of Clinical Microbiology, 2002, 40, 3865-3866.	3.9	30
207	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis, 2012, 225, 200-207.	0.8	30
208	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 207-212.	2.1	30
209	SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 4804-4813.	3.2	30
210	Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. Aids, 2015, 29, 1811-1820.	2.2	29
211	The Changing Face of HIV/AIDS in Treated Patients. Current HIV Research, 2009, 7, 365-377.	0.5	28
212	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Research, 2010, 88, 281-286.	4.1	28
213	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2358-2362.	3.0	28
214	Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. Aids, 2000, 14, 469.	2.2	28
215	A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease. Antimicrobial Agents and Chemotherapy, 2000, 44, 1132-1139.	3.2	27
216	Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Research, 2006, 69, 173-180.	4.1	27

#	Article	IF	CITATIONS
217	Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Research, 2007, 123, 161-169.	2.2	27
218	Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antiviral Research, 2011, 92, 479-483.	4.1	27
219	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	2.5	27
220	ADAR1 affects HCV infection by modulating innate immune response. Antiviral Research, 2018, 156, 116-127.	4.1	27
221	Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2004, 12, 119-24.	2.9	27
222	Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals. Journal of Virology, 2002, 76, 12344-12348.	3.4	26
223	Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions. Journal of Clinical Microbiology, 2004, 42, 1620-1625.	3.9	26
224	Longitudinal Study on Mitochondrial Effects of Didanosine–Tenofovir Combination. AIDS Research and Human Retroviruses, 2006, 22, 33-39.	1.1	26
225	Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. Aids, 2008, 22, 2053-2067.	2.2	26
226	HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. Antiviral Research, 2009, 83, 94-98.	4.1	26
227	Gene editing using a zinc-finger nuclease mimicking the CCR5î"32 mutation induces resistance to CCR5-using HIV-1. Journal of Antimicrobial Chemotherapy, 2014, 69, 1755-1759.	3.0	26
228	Characterization of the Influence of Mediator Complex in HIV-1 Transcription. Journal of Biological Chemistry, 2014, 289, 27665-27676.	3.4	26
229	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. Journal of Antimicrobial Chemotherapy, 2014, 69, 3057-3060.	3.0	26
230	Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naive, HIV-Infected Patients. Antiviral Therapy, 2006, 11, 47-51.	1.0	26
231	Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. Aids, 1999, 13, 547-555.	2.2	25
232	Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies. Clinical Infectious Diseases, 2005, 41, 901-905.	5.8	25
233	ADS-J1 Inhibits HIV-1 Entry by Interacting with gp120 and Does Not Block Fusion-Active gp41 Core Formation. Antimicrobial Agents and Chemotherapy, 2010, 54, 4487-4492.	3.2	25
234	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. Antiviral Therapy, 2003, 8, 155-161.	1.0	25

#	Article	IF	CITATIONS
235	Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2008, 52, 3928-3932.	3.2	24
236	Epidemiological Data of Different Human Papillomavirus Genotypes in Cervical Specimens of HIV-1-Infected Women Without History of Cervical Pathology. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 168-175.	2.1	24
237	Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 72-75.	3.2	24
238	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.	1.0	24
239	Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. Journal of Virology, 2003, 77, 4389-4395.	3.4	23
240	Lack of Evidence for Protease Evolution in HIVâ€1–Infected Patients after 2 Years of Successful Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 189, 1444-1451.	4.0	23
241	Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. Journal of Virology, 2007, 81, 4713-4721.	3.4	23
242	Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. Antimicrobial Agents and Chemotherapy, 2010, 54, 3047-3048.	3.2	23
243	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology, 2012, 9, 81.	2.0	23
244	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Frontiers in Immunology, 2020, 11, 418.	4.8	23
245	Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. Microbiology (United Kingdom), 2000, 81, 85-95.	1.8	23
246	Resistance of the Human Immunodeficiency Virus to the Inhibitory Action of Negatively Charged Albumins on Virus Binding to CD4. AIDS Research and Human Retroviruses, 1999, 15, 1535-1543.	1.1	22
247	HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure. Clinical Infectious Diseases, 2005, 41, 729-737.	5.8	22
248	Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein. Antimicrobial Agents and Chemotherapy, 2005, 49, 4296-4304.	3.2	22
249	Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations. HIV Clinical Trials, 2006, 7, 86-96.	2.0	22
250	Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	22
251	Raltegravir Susceptibility and Fitness Progression of HIV Type-1 Integrase in Patients on Long-Term Antiretroviral Therapy. Antiviral Therapy, 2008, 13, 881-893.	1.0	22
252	Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV–Hiv-Coinfected Patients. Antiviral Therapy, 2008, 13, 1047-1055.	1.0	22

#	Article	IF	CITATIONS
253	Inhibition of HIV-1 replication by RNA interference of p53 expression. Journal of Leukocyte Biology, 2006, 80, 659-667.	3.3	21
254	β5 Integrin Is the Major Contributor to the αv Integrin-Mediated Blockade of HIV-1 Replication. Journal of Immunology, 2011, 186, 464-470.	0.8	21
255	HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation. Journal of Immunology, 2012, 188, 6036-6045.	0.8	21
256	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 152-160.	2.1	21
257	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2015, 70, 1139-1145.	3.0	21
258	Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile. PLoS ONE, 2012, 7, e37442.	2.5	21
259	Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response. Antiviral Therapy, 2006, 11, 473-482.	1.0	21
260	Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption. Antiviral Therapy, 2008, 13, 945-951.	1.0	21
261	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. Journal of Antimicrobial Chemotherapy, 2011, 66, 358-362.	3.0	20
262	Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2019, 35, 513-518.	1.1	20
263	First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain. Viruses, 2021, 13, 2526.	3.3	20
264	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. Virology, 2001, 285, 356-365.	2.4	19
265	Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment. Clinical Pharmacokinetics, 2007, 46, 85-92.	3.5	19
266	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. Journal of Infectious Diseases, 2011, 204, 741-752.	4.0	19
267	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. PLoS ONE, 2014, 9, e107625.	2.5	19
268	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. American Journal of Men's Health, 2017, 11, 647-653.	1.6	19
269	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1940-1948.	3.0	19
270	Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. Aids, 2001, 15, 1904-1906.	2.2	19

#	Article	IF	CITATIONS
271	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. Microbiome, 2022, 10, 59.	11.1	19
272	Genetic Screen for Monitoring Hepatitis C Virus NS3 Serine Protease Activity. Antimicrobial Agents and Chemotherapy, 2003, 47, 1760-1765.	3.2	18
273	Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 313-316.	2.1	18
274	Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. Journal of Antimicrobial Chemotherapy, 2010, 65, 417-424.	3.0	18
275	Diverse combinatorial design, synthesis and inÂvitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 159-174.	5.5	18
276	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. Journal of Infectious Diseases, 2015, 211, 936-946.	4.0	18
277	SAMHD1 is active in cycling cells permissive to HIV-1 infection. Antiviral Research, 2017, 142, 123-135.	4.1	18
278	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	6.5	18
279	3′-Azido-2′,3′-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. Antiviral Therapy, 2 11, 803-812.	2006,	18
280	Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. Journal of Medical Virology, 2001, 63, 85-87.	5.0	17
281	Genetic Screen for Monitoring Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease. Journal of Virology, 2004, 78, 14057-14061.	3.4	17
282	Discovery of Novel Non yclam Polynitrogenated CXCR4 Coreceptor Inhibitors. ChemMedChem, 2008, 3, 1549-1557.	3.2	17
283	HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. Virology, 2008, 372, 421-429.	2.4	17
284	A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Research, 2008, 131, 260-270.	2.2	17
285	Novel Monocyclam Derivatives as HIV Entry Inhibitors: Design, Synthesis, Antiâ€HIV Evaluation, and Their Interaction with the CXCR4 Coâ€receptor. ChemMedChem, 2010, 5, 1272-1281.	3.2	17
286	RNA Interference as a Tool for Exploring HIV-1 Robustness. Journal of Molecular Biology, 2011, 413, 84-96.	4.2	17
287	Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). Aids, 2011, 25, 1557-1583.	2.2	17
288	Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients. Journal of Virology, 2011, 85, 5961-5969.	3.4	17

#	Article	IF	CITATIONS
289	Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. Aids, 2014, 28, 2157-2159.	2.2	17
290	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
291	HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic. Scientific Reports, 2019, 9, 5544.	3.3	17
292	A Specific Mobile Health Application for Older HIV-Infected Patients: Usability and Patient's Satisfaction. Telemedicine Journal and E-Health, 2021, 27, 432-440.	2.8	17
293	Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Reviews, 2004, 6, 123-30.	1.0	17
294	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. Antiviral Therapy, 2005, 10, 825-832.	1.0	17
295	Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. Aids, 2009, 23, 266-268.	2.2	16
296	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. Antiviral Therapy, 2011, 16, 667-675.	1.0	16
297	P-glycoprotein (<i>ABCB1</i>) activity decreases raltegravir disposition in primary CD4+P-gp ^{high} cells and correlates with HIV-1 viral load. Journal of Antimicrobial Chemotherapy, 2016, 71, 2782-2792.	3.0	16
298	Human Papillomavirus 16 Integration and Risk Factors Associated in Anal Samples of HIV-1 Infected Men. Sexually Transmitted Diseases, 2010, 37, 311-315.	1.7	16
299	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. PLoS ONE, 2012, 7, e46031.	2.5	16
300	Catalytic Efficiency and Phenotype of HIV-1 Proteases Encoding Single Critical Resistance Substitutions. Virology, 2002, 300, 71-78.	2.4	15
301	Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects. AIDS Research and Human Retroviruses, 2004, 20, 1283-1288.	1.1	15
302	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. Aids, 2013, 27, 1375-1385.	2.2	15
303	Zinc Finger Endonuclease Targeting <i>PSIP1</i> Inhibits HIV-1 Integration. Antimicrobial Agents and Chemotherapy, 2014, 58, 4318-4327.	3.2	15
304	Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 2564-2566.	3.2	15
305	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. Frontiers in Immunology, 2018, 9, 2429.	4.8	15
306	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. Aids, 2001, 15, 1890-1892.	2.2	15

#	Article	IF	CITATIONS
307	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. PLoS ONE, 2014, 9, e87334.	2.5	15
308	Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern. Frontiers in Microbiology, 2022, 13, .	3.5	15
309	Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 5907-5913.	3.4	14
310	CCR5 Inhibitors: Promising yet Challenging. Journal of Infectious Diseases, 2007, 196, 178-180.	4.0	14
311	Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression. HIV Clinical Trials, 2009, 10, 432-438.	2.0	14
312	Long-term HIV-1 infection induces an antiviral state in primary macrophages. Antiviral Research, 2016, 133, 145-155.	4.1	14
313	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. Retrovirology, 2016, 13, 51.	2.0	14
314	Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers, 2020, 12, 713.	3.7	14
315	Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. Journal of General Virology, 2006, 87, 1285-1294.	2.9	13
316	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. Journal of NeuroVirology, 2010, 16, 208-218.	2.1	13
317	Human Papillomavirus Genotype Distribution and Human Papillomavirus 16 and Human Papillomavirus 18 Genomic Integration in Invasive and In Situ Cervical Carcinoma in Human Immunodeficiency Virus-Infected Women. International Journal of Gynecological Cancer, 2011, 21, 1486-1490.	2.5	13
318	Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 901-911.	3.0	13
319	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. PLoS ONE, 2012, 7, e30330.	2.5	13
320	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.5	13
321	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. Journal of Antimicrobial Chemotherapy, 2015, 70, 1124-1129.	3.0	13
322	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. Journal of Antimicrobial Chemotherapy, 2015, 70, 3087-3095.	3.0	13
323	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Scientific Reports, 2017, 7, 3717.	3.3	13
324	Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 732-737.	3.0	13

#	Article	IF	CITATIONS
325	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. AIDS Research and Human Retroviruses, 2002, 18, 27-38.	1.1	12
326	Endoribonuclease-Prepared Short Interfering RNAs Induce Effective and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2007, 81, 10680-10686.	3.4	12
327	Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 109-117.	2.1	12
328	The reconstitution of the thymus in immunosuppressed individuals restores CD4â€specific cellular and humoral immune responses. Immunology, 2011, 133, 318-328.	4.4	12
329	Trans-infection but Not Infection from within Endosomal Compartments after Cell-to-cell HIV-1 Transfer to CD4+ T Cells. Journal of Biological Chemistry, 2012, 287, 32017-32026.	3.4	12
330	HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization. PLoS ONE, 2013, 8, e67085.	2.5	12
331	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	3.3	12
332	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	3.3	12
333	Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men. PLoS ONE, 2018, 13, e0199033.	2.5	12
334	Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. Journal of Antimicrobial Chemotherapy, 2007, 61, 400-404.	3.0	11
335	Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8 + T Cells. Journal of Virology, 2016, 90, 8552-8562.	3.4	11
336	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study. PLoS ONE, 2014, 9, e84676.	2.5	11
337	Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antiviral Therapy, 2004, 9, 335-42.	1.0	11
338	Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs. Antimicrobial Agents and Chemotherapy, 2005, 49, 3926-3929.	3.2	10
339	Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. Antiviral Therapy, 2010, 15, 219-225.	1.0	10
340	Could CD4 Capture by <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtext>CD</mml:mtext><mml:msup>< mathvariant="bold">8<mml:mo mathvariant="bold">+</mml:mo </mml:msup></mml:mrow>T Cells Play a Role in HIV Spragding2</mml:math 	mml:mn 3.0	10
341	Spreading?. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10. Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, e5-e8.	2.1	10
342	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. Aids, 2016, 30, 2275-2287.	2.2	10

#	Article	IF	CITATIONS
343	Absence of Genetic Diversity Reduction in the HIV-1 Integrated Proviral LTR Sequence Population during Successful Combination Therapy. Virology, 2001, 282, 1-5.	2.4	9
344	Review: Immunologic Response to Protease Inhibitor-Based Highly Active Antiretroviral Therapy: A Review. AIDS Patient Care and STDs, 2007, 21, 609-620.	2.5	9
345	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine, 2011, 29, 5711-5724.	3.8	9
346	Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines. Journal of Biomolecular Screening, 2012, 17, 727-737.	2.6	9
347	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	3.0	9
348	Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. AIDS Research and Human Retroviruses, 2016, 32, 452-455.	1.1	9
349	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	12.2	9
350	Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study. Antiviral Therapy, 2004, 9, 889-893.	1.0	9
351	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. Aids, 2001, 15, 999-1008.	2.2	8
352	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2007, 61, 206-209.	3.0	8
353	A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 335-337.	2.1	8
354	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. Retrovirology, 2012, 9, 15.	2.0	8
355	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/Ml. Antiviral Therapy, 2014, 19, 569-577.	1.0	8
356	Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. PLoS ONE, 2017, 12, e0182547.	2.5	8
357	Natural History of Anal Squamous Intraepithelial Lesions in HIV-Positive Men with Normal Baseline Cytology. AIDS Patient Care and STDs, 2019, 33, 459-465.	2.5	8
358	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS ONE, 2019, 14, e0210965.	2.5	8
359	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. Antiviral Research, 2019, 168, 18-27.	4.1	8
360	Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2005, 55, 824-827.	3.0	7

#	Article	IF	CITATIONS
361	Analysis of Chemokine and Cytokine Expression in Patients with HIV and GB Virus Type C Coinfection. Clinical Infectious Diseases, 2005, 40, 1342-1349.	5.8	7
362	Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses, 2011, 27, 713-717.	1.1	7
363	Learning from drug changes in antiretroviral therapy. Aids, 2013, 27, 833-834.	2.2	7
364	Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection. Antiviral Therapy, 2014, 20, 307-315.	1.0	7
365	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 201-205.	2.1	7
366	HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy. Journal of Antimicrobial Chemotherapy, 2020, 75, 2535-2546.	3.0	7
367	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. Journal of Antimicrobial Chemotherapy, 2021, 76, 827-829.	3.0	7
368	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study. Antiviral Therapy, 2004, 9, 787-800.	1.0	7
369	A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. Journal of Antimicrobial Chemotherapy, 2008, 62, 1374-1378.	3.0	6
370	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. Aids, 2008, 22, 737-740.	2.2	6
371	Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?. AIDS Research and Therapy, 2009, 6, 2.	1.7	6
372	Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. Therapeutic Drug Monitoring, 2010, 32, 93-96.	2.0	6
373	Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. Journal of Clinical Microbiology, 2012, 50, 3909-3916.	3.9	6
374	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. Journal of the International AIDS Society, 2014, 17, 19550.	3.0	6
375	Cost–effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 16-20.	0.5	6
376	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of Pls. Journal of Antimicrobial Chemotherapy, 2018, 73, 2452-2459.	3.0	6
377	Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. Aids, 2021, 35, 2497-2502.	2.2	6
378	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	4.8	6

#	Article	IF	CITATIONS
379	HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32. Immunobiology, 2013, 218, 543-547.	1.9	5
380	Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages. Expert Review of Anti-Infective Therapy, 2014, 12, 947-957.	4.4	5
381	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-NaÃ⁻ve Chronically HIV-1 Infected Individuals. PLoS ONE, 2015, 10, e0120648.	2.5	5
382	Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens. Antiviral Therapy, 2008, 13, 231-240.	1.0	5
383	Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. Aids, 2006, 20, 1896-1898.	2.2	4
384	Drug-Resistance Mutations Number and K70R or T215Y/F Substitutions Predict Treatment Resumption during Guided Treatment Interruptions. AIDS Research and Human Retroviruses, 2008, 24, 725-732.	1.1	4
385	The Magnitude of Interferon-Î ³ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 507-512.	2.1	4
386	A Step Ahead on the HIV Collaboratory. Science, 2009, 324, 1264-1265.	12.6	4
387	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1462-1469.	3.0	4
388	Management of bone mineral density in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2016, 17, 845-852.	1.8	4
389	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. PLoS ONE, 2015, 10, e0128131.	2.5	4
390	HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission. Pathogens, 2022, 11, 39.	2.8	4
391	New antiretroviral drugs and approaches to HIV treatment. Aids, 2003, 17, S85-S96.	2.2	3
392	Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification. Journal of Clinical Microbiology, 2005, 43, 436-438.	3.9	3
393	Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients. Pharmacoeconomics, 2010, 28, 69-81.	3.3	3
394	Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV–HCV-coinfected patients: results from the CORAL-2 study. Antiviral Therapy, 2011, 16, 833-841.	1.0	3
395	Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1â^'coinfected patients. Aids, 2012, 26, 1973-1974.	2.2	3
396	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. Future Virology, 2012, 7, 1127-1134.	1.8	3

#	Article	IF	CITATIONS
397	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine, 2013, 11, 48.	4.4	3
398	Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. Virology Journal, 2013, 10, 350.	3.4	3
399	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1346-1351.	3.0	3
400	TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses. Journal of Immunology, 2020, 205, 3348-3357.	0.8	3
401	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE, 2020, 15, e0238575.	2.5	3
402	Genotypic and phenotypic evolution of HIV type-1 protease during <i>in vitro</i> sequential or concomitant combination of atazanavir and amprenavir. Antiviral Therapy, 2010, 15, 431-436.	1.0	2
403	Efficacy and Safety of Ritonavir Dose Reduction Based on the Tipranavir Inhibitory Quotient in HIV-Infected Patients on Salvage Antiretroviral Therapy with Tipranavir/Ritonavir. AIDS Research and Human Retroviruses, 2010, 26, 1191-1196.	1.1	2
404	Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 1455-1472.	2.8	2
405	Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study. Pathogens, 2021, 10, 208.	2.8	2
406	Clinical approach to drug resistance interpretation: expert advice. Current Opinion in HIV and AIDS, 2007, 2, 145-149.	3.8	1
407	Compromised Immunologic Recovery in Patients Receiving Tipranavir/Ritonavir Coadministered With Tenofovir and Didanosine in Randomized Evaluation of Strategic Intervention in multidrug-reSistant patients with Tipranavir (RESIST) Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 479-481.	2.1	1
408	The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, e46-e48.	2.1	1
409	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged>70 years: a comparative cohort study (Over50 cohort). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-8.	1.2	1
410	Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both. Antiviral Therapy, 2004, 9, 969-977.	1.0	1
411	Cost–effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 16-20.	0.3	0